Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer

Overview of attention for article published in BMC Cancer, December 2019

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

policy: 1 policy source

twitter: 2 X users

Citations

dimensions_citation: 19 Dimensions

Readers on

mendeley: 36 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 3 policy documents that reference this research output.

Stereotactic Ablative Radiotherapy for the Treatment of Oligometastatic Cancer

Cited by Canadian Agency for Drugs and Technologies in Health on 20 Jun 2022

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Stereotactic Ablative Radiotherapy for the Treatment of Oligometastatic Cancer

Cited by Canadian Agency for Drugs and Technologies in Health on 24 Jun 2021

Stereotactic Ablative Radiotherapy for the Treatment of Oligometastatic Cancer

Cited by Canadian Agency for Drugs and Technologies in Health on 24 Apr 2020

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.